← Eichor
Condition: Follicular T Cell Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Follicular T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07293403Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
Phase 2 · 1 location(s) · Peking University · NCT06347653Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular H
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05572983CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Phase 2 · 1 location(s) · Liping Dou · NCT07587840Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05326243Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Pr
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05958719Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Marcela V. Maus, M.D.,Ph.D. · NCT06026319Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Italian Observational Study on CAR-T Therapy for Lymphoma
Phase N/A · 1 location(s) · Paolo Corradini · NCT06339255Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · John Lister · NCT05281809Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/Phase 2 · 2 location(s) · Curocell Inc. · NCT04836507Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antige
Phase 2 · 1 location(s) · University of California, Davis · NCT06854159CAR-T Followed by Bispecific Antibodies
Phase 2 · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04889716A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Ref
Phase 1 · 1 location(s) · GenomeFrontier Therapeutics TW Co., Ltd. · NCT06703892Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
Phase 1/Phase 2 · 1 location(s) · Won Seog Kim · NCT05230680Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/Phase 2 · 34 location(s) · Lyell Immunopharma, Inc. · NCT05826535A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R
Phase 1/Phase 2 · 31 location(s) · AstraZeneca · NCT06542250Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373REal World Data in LYmphoma and Survival in Adults
Phase N/A · 37 location(s) · Hospices Civils de Lyon · NCT03869619A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT059781413'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Long-term Follow-up Study of Patients Receiving CAR-T Cells
Phase N/A · 1 location(s) · Medical College of Wisconsin · NCT03375619
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.